Silibinin restores the sensitivity of cisplatin and taxol in A2780-resistant cell and reduces drug-induced hepatotoxicity

References

• Matulonis UA. Highlights in ovarian cancer from the 2017 American Society of clinical oncology annual meeting: commentary. Clin Adv Hematol Oncol. 2017;7(8):13–17.
   Google Scholar
• Goodman MT, Howe HL, Tung KH, et al. Incidence of ovarian cancer by race and ethnicity in the United States, 1992–1997. Cancer. 2003;97(10 Suppl):2676–2685. doi:10.1002/cncr.1134912733132
   PubMed Web of Science ®Google Scholar
• Sehouli J, Senyuva F, Fotopoulou C, et al. Intra-abdominal tumor dissemination pattern and surgical outcome in 214 patients with primary ovarian cancer. J Surg Oncol. 2009;99(7):424–427. doi:10.1002/jso.2128819365809
   PubMed Web of Science ®Google Scholar
• Luvero D, Milani A, Ledermann JA. Treatment options in recurrent ovarian cancer: latest evidence and clinical potential. Ther Adv Med Oncol. 2014;6(5):229–239. doi:10.1177/175883401454412125342990
   PubMed Web of Science ®Google Scholar
• Bagnato A, Rosano L. Understanding and overcoming chemoresistance in ovarian cancer: emerging role of the endothelin axis. Curr Oncol. 2012;19(1):36–38. doi:10.3747/co.19.89522328840
   PubMed Web of Science ®Google Scholar
• Weinstein RS, Jakate SM, Dominguez JM, et al. Relationship of the expression of the multidrug resistance gene product (P-glycoprotein) in human colon carcinoma to local tumor aggressiveness and lymph node metastasis. Cancer Res. 1991;51(10):2720–2726.1673639
   PubMed Web of Science ®Google Scholar
• Osmak M, Niksic D, Brozovic A, Ristov AA, Vrhovec I, Skrk J. Drug resstant tumor cells have increased levels of tumor markers for invasion and metastasis. Anticancer Res. 1999;19(4B):3193–3197.10652611
   PubMed Web of Science ®Google Scholar
• De Larco JE, Wuertz BR, Manivel JC, et al. Progression and enhancement of metastatic potential after exposure of tumor cells to chemotherapeutic agents. Cancer Res. 2001;61(7):2857–2861.11306458
   PubMed Web of Science ®Google Scholar
• Al-Farsi A, Ellis PM. Treatment paradigms for patients with metastatic non-small cell lung cancer, squamous lung cancer: first, second, and third-line. Front Oncol. 2014;4:157. doi:10.3389/fonc.2014.0015725019058
   PubMedGoogle Scholar
• Park BK, Kitteringham NR, Maggs JL, et al. The role of metabolic activation in drug-induced hepatotoxicity. Annu Rev Pharmacol Toxicol. 2005;45:177–202. doi:10.1146/annurev.pharmtox.45.120403.10005815822174
   PubMed Web of Science ®Google Scholar
• Ferenci P, Dragosics B, Dittrich H, et al. Randomized controlled trial of silymarin treatment in patients with cirrhosis of the liver. J Hepatol. 1989;9(1):105–113.2671116
   PubMed Web of Science ®Google Scholar
• Deep G, Agarwal R. Antimetastatic efficacy of silibinin: molecular mechanisms and therapeutic potential against cancer. Cancer Metastasis Rev. 2010;29(3):447–463. doi:10.1007/s10555-010-9237-020714788
   PubMed Web of Science ®Google Scholar
• Cho HJ, Suh DS, Moon SH, et al. Silibinin inhibits tumor growth through downregulation of extracellular signal-regulated kinase and Akt in vitro and in vivo in human ovarian cancer cells. J Agric Food Chem. 2013;61(17):4089–4096. doi:10.1021/jf400192v23570653
   PubMed Web of Science ®Google Scholar
• Momeny M, Ghasemi R, Valenti G, et al. Effects of silibinin on growth and invasive properties of human ovarian carcinoma cells through suppression of heregulin/HER3 pathway. Tumour Biol. 2016;37(3):3913–3923. doi:10.1007/s13277-015-4220-626482609
   PubMedGoogle Scholar
• Giacomelli S, Gallo D, Apollonio P, et al. Silybin and its bioavailable phospholipid complex (IdB 1016) potentiate in vitro and in vivo the activity of cisplatin. Life Sci. 2002;70(12):1447–1459.11883719
   PubMed Web of Science ®Google Scholar
• Singh RP, Agarwal R. Mechanisms and preclinical efficacy of silibinin in preventing skin cancer. Eur J Cancer. 2005;41(13):1969–1979. doi:10.1016/j.ejca.2005.03.03316084079
   PubMed Web of Science ®Google Scholar
• Sharma G, Singh RP, Chan DC, et al. Silibinin induces growth inhibition and apoptotic cell death in human lung carcinoma cells. Anticancer Res. 2003;23(3B):2649–2655.12894553
   PubMed Web of Science ®Google Scholar
• Flaig TW, Gustafson DL, Su LJ, et al. A phase I and pharmacokinetic study of silybin-phytosome in prostate cancer patients. Invest New Drugs. 2007;25(2):139–146. doi:10.1007/s10637-006-9019-217077998
   PubMed Web of Science ®Google Scholar
• Chen Y, Deng Z, Jiang S, et al. Human cells lacking coilin and Cajal bodies are proficient in telomerase assembly, trafficking and telomere maintenance. Nucleic Acids Res. 2015;43(1):385–395. doi:10.1093/nar/gku127725477378
   PubMed Web of Science ®Google Scholar
• Li D, Huang Q, Lu M, et al. The organophosphate insecticide chlorpyrifos confers its genotoxic effects by inducing DNA damage and cell apoptosis. Chemosphere. 2015;135:387–393. doi:10.1016/j.chemosphere.2015.05.02426002045
   PubMed Web of Science ®Google Scholar
• Harrigan JA, Belotserkovskaya R, Coates J, et al. Replication stress induces 53BP1-containing OPT domains in G1 cells. J Cell Biol. 2011;193(1):97–108. doi:10.1083/jcb.20101108321444690
   PubMed Web of Science ®Google Scholar
• Lukas C, Savic V, Bekker-Jensen S, et al. 53BP1 nuclear bodies form around DNA lesions generated by mitotic transmission of chromosomes under replication stress. Nat Cell Biol. 2011;13(3):243–253. doi:10.1038/ncb220121317883
   PubMed Web of Science ®Google Scholar
• Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108. doi:10.3322/caac.2126225651787
   PubMed Web of Science ®Google Scholar
• Dasari S, Tchounwou PB. Cisplatin in cancer therapy: molecular mechanisms of action. Eur J Pharmacol. 2014;740:364–378. doi:10.1016/j.ejphar.2014.07.02525058905
   PubMed Web of Science ®Google Scholar
• Bijak M, Synowiec E, Sitarek P, et al. Evaluation of the cytotoxicity and genotoxicity of flavonolignans in different cellular models. Nutrients. 2017;9(12):1356. doi:10.3390/nu9121356
   PubMed Web of Science ®Google Scholar
• Tyagi AK, Agarwal C, Chan DC, et al. Synergistic anti-cancer effects of silibinin with conventional cytotoxic agents doxorubicin, cisplatin and carboplatin against human breast carcinoma MCF-7 and MDA-MB468 cells. Oncol Rep. 2004;11(2):493–499.14719089
   PubMed Web of Science ®Google Scholar
• Scambia G, De Vincenzo R, Ranelletti FO, et al. Antiproliferative effect of silybin on gynaecological malignancies: synergism with cisplatin and doxorubicin. Eur J Cancer. 1996;32A:877–882.9081370
   PubMed Web of Science ®Google Scholar
• Fatima PA, Roghiyeh PA, Khodadad K, et al. Enhancement of anticancer activity by silibinin and paclitaxel combination on the ovarian cancer. Artif Cell Nanomed B. 2018;46(7):1483–1487. doi:10.1080/21691401.2017.1374281
   PubMed Web of Science ®Google Scholar
• Zhou L, Liu P, Chen B, et al. Silibinin restores paclitaxel sensitivity to paclitaxel-resistant human ovarian carcinoma cells. Anticancer Res. 2008;28:1119–1128.18507063
   PubMed Web of Science ®Google Scholar
• Nikolaou M, Pavlopoulou A, Georgakilas AG, et al. The challenge of drug resistance in cancer treatment: a current overview. Clin Exp Metastasis. 2018;35(4):309–318. doi:10.1007/s10585-018-9903-029799080
   PubMed Web of Science ®Google Scholar
• Robert J. Biology of cancer metastasis. Bull Cancer. 2013;168(4):670–691.
   Google Scholar
• Maor Y, Malnick S. Liver injury induced by anticancer chemotherapy and radiation therapy. Int J Hepatol. 2013;2013:815105. doi:10.1155/2013/81510523970972
   PubMedGoogle Scholar
• Lim SC, Choi JE, Kang HS, et al. Ursodeoxycholic acid switches oxaliplatin-induced necrosis to apoptosis by inhibiting reactive oxygen species production and activating p53-caspase 8 pathway in HepG2 hepatocellular carcinoma. Int J Cancer. 2010;126(7):1582–1595. doi:10.1002/ijc.2485319728331
   PubMed Web of Science ®Google Scholar
• Lee B, Lee DG. Reactive oxygen species depletion by silibinin stimulates apoptosis-like death in escherichia coli. J Microbiol Biotechnol. 2017;27(12):2129–2140. doi:10.4014/jmb.1710.1002929121705
   PubMed Web of Science ®Google Scholar